SNHG7

Summary

SNHG7 (small nucleolar RNA host gene 7, HGNC:28254) is a long non-coding RNA gene on chromosome 9q34.3.

Predicted to be involved in RNA processing. Predicted to be located in nucleolus.

Source: NCBI Gene 84973 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28254
Approved symbol	SNHG7
Name	small nucleolar RNA host gene 7
Location	9q34.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	MGC16037, NCRNA00061
Ensembl gene	ENSG00000233016
Ensembl biotype	lncRNA
Entrez	84973
RNAcentral	URS000075E30B — lncRNA, 2176 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 38 lncRNA

ENST00000414282, ENST00000416970, ENST00000436596, ENST00000447221, ENST00000653276, ENST00000663097, ENST00000668354, ENST00000685573, ENST00000686963, ENST00000701938, ENST00000761648, ENST00000761649, ENST00000761650, ENST00000761651, ENST00000761652, ENST00000761653, ENST00000761654, ENST00000761655, ENST00000761656, ENST00000761657, ENST00000761658, ENST00000761659, ENST00000761660, ENST00000761661, ENST00000761662, ENST00000761663, ENST00000761664, ENST00000761665, ENST00000761666, ENST00000761667, ENST00000761668, ENST00000761669, ENST00000761670, ENST00000761671, ENST00000761672, ENST00000761673, ENST00000761674, ENST00000761675

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000414282 — 6 exons

Exon	Start	End
ENSE00001597800	136723897	136724000
ENSE00001605356	136726311	136726416
ENSE00001666922	136721366	136723111
ENSE00001732850	136727046	136727086
ENSE00001772577	136725055	136725110
ENSE00001790852	136727881	136728184

Expression profiles

Bgee: expression breadth ubiquitous, 171 present calls, max score 97.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.4578 / max 919.3369, expressed in 1798 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103192	33.4578	1798

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	97.52	gold quality
right lung	UBERON:0002167	96.94	gold quality
left ovary	UBERON:0002119	96.79	gold quality
right uterine tube	UBERON:0001302	96.66	gold quality
lower esophagus mucosa	UBERON:0035834	96.55	gold quality
right ovary	UBERON:0002118	96.02	gold quality
endocervix	UBERON:0000458	95.60	gold quality
body of uterus	UBERON:0009853	95.40	gold quality
left uterine tube	UBERON:0001303	95.25	gold quality
ectocervix	UBERON:0012249	95.11	gold quality
left lobe of thyroid gland	UBERON:0001120	94.81	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.79	gold quality
sural nerve	UBERON:0015488	94.77	gold quality
lower esophagus	UBERON:0013473	94.63	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.61	gold quality
right lobe of thyroid gland	UBERON:0001119	94.60	gold quality
body of stomach	UBERON:0001161	94.21	gold quality
skin of abdomen	UBERON:0001416	94.13	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.06	gold quality
upper lobe of left lung	UBERON:0008952	93.77	gold quality
colonic epithelium	UBERON:0000397	93.63	gold quality
skin of leg	UBERON:0001511	93.58	gold quality
cerebellar hemisphere	UBERON:0002245	93.37	gold quality
tibial nerve	UBERON:0001323	93.35	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.33	gold quality
omental fat pad	UBERON:0010414	93.33	gold quality
cerebellar cortex	UBERON:0002129	93.31	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.28	gold quality
minor salivary gland	UBERON:0001830	93.27	gold quality
peritoneum	UBERON:0002358	93.24	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	68.92
E-ANND-3	yes	12.02

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• our research showed that lncRNA-SNHG7 promotes the proliferation, migration and invasion, and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression, suggesting that lncRNA-SNHG7 as a key regulator of gene expression, may be a promising therapeutic strategy for the treatment of lung cancer (PMID:27666964)
• SNHG7 expression was interfered, in vivo tumor growth was inhibited, and the Western blotting assay revealed that regulation of p15 and p16 expressions constituted a part of the potential molecular mechanism. (PMID:29131253)
• SNHG7 promoted the proliferation, migration and invasion of glioblastoma cells through the inhibition of miR-5095 and concomitant activation of Wnt/beta-catenin signaling pathway. (PMID:29360452)
• Our results present that SNHG7 regulates the cycle progression and acts as an oncogenic gene in the prostate cancer tumorigenesis via miR-503/Cyclin D1 pathway. (PMID:29571017)
• SNHG7 can partly promote the development of esophageal cancer by regulating the expression of p15 and p16 to promote cell proliferation and inhibiting apoptosis. (PMID:29771415)
• SNHG7 positively regulated GALNT1 level through sponging miR-216b, and played an oncogenic role in colorectal cancer progression. (PMID:29915311)
• SNHG7 promoted CRC cell proliferation, metastasis, mediated cell cycle, and inhibited apoptosis. (PMID:29970122)
• The targets of miR-34a could be upregulated by SNHG7, including proliferation-related Notch1, apoptosis-related BCL-2, cell cycle-related CDK6, and EMT-related SMAD4. The oncogene role of SNHG7 in vivo was also confirmed and found that knockdown of SNHG7 delayed the tumor growth with increased miR-34a level and Ki-67 level in OS tissues. (PMID:29989838)
• SNHG7 elicited carcinogenic functions in bladder cancer partially via activating Wnt/beta-catenin signaling pathway (PMID:30527358)
• SNHG7 is highly expressed in breast cancer (BC), which is correlated to tumor stage, lymph node metastasis and distant metastasis; SNHG7 could promote malignant progression of BC by regulating microRNA-186. (PMID:30536320)
• results suggested that SNHG7 is a potential molecular target for attenuating high-glucose-induced angiogenesis in the diabetic retinopathy through regulation of the miR-543-mediated SIRT1/VEGF pathway (PMID:31056258)
• LncRNA SNHG7 participates in osteosarcoma progression by down-regulating p53 via binding to DNMT1. (PMID:31114984)
• SNHG7 promoted breast cancer tumorigenesis and progression by sponging miR-34a through EMT initiation and the Notch-1 pathway (PMID:31132353)
• Knockdown of long noncoding RNA SNHG7 inhibits the proliferation and promotes apoptosis of thyroid cancer cells by downregulating BDNF. (PMID:31210313)
• Long non-coding RNA (lncRNA) small nucleolar RNA host gene 7 (SNHG7) promotes breast cancer progression by sponging miRNA-381. (PMID:31378900)
• SNHG7 contributed to hepatocellular carcinoma progression by regulating miR-122-5p and RPL4. (PMID:31545291)
• miR-146a interacting with lncRNA EPB41L4A-AS1 and lncRNA SNHG7 inhibits proliferation of bone marrow-derived mesenchymal stem cells. (PMID:31612476)
• Data show that upregulated small nucleolar RNA host gene 7 (SNHG7) in colon advanced adenomas and early-stage cancer negatively correlates with miR-193b level. (PMID:31721543)
• LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer. (PMID:31773679)
• Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis. (PMID:31793741)
• SNHG7 accelerates cell migration and invasion through regulating miR-34a-Snail-EMT axis in gastric cancer. (PMID:31814518)
• Study showed that lncRNA-SNHG7 was overexpressed in prostate cancer tissues, and it might contributes to the development and progression of prostate cancer. Furthermore, the SNHG7 expression was associated with the prognosis of prostate cancer, suggesting a potential target for the treatment and prognosis of prostate cancer. (PMID:32049793)
• Long Noncoding RNA SNHG7 Activates Wnt/beta-Catenin Signaling Pathway in Cervical Cancer Cells by Epigenetically Silencing DKK1. (PMID:32275170)
• LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis. (PMID:32329857)
• LncRNA SNHG7 promotes the proliferation of nasopharyngeal carcinoma by miR-514a-5p/ELAVL1 axis. (PMID:32370736)
• SNHG7 Facilitates Hepatocellular Carcinoma Occurrence by Sequestering miR-9-5p to Upregulate CNNM1 Expression. (PMID:32397799)
• Long non-coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer. (PMID:32420685)
• SNHG7 is a lncRNA oncogene controlled by Insulin-like Growth Factor signaling through a negative feedback loop to tightly regulate proliferation. (PMID:32444795)
• Metformin Affects Paclitaxel Sensitivity of Ovarian Cancer Cells Through Autophagy Mediated by Long Noncoding RNASNHG7/miR-3127-5p Axis. (PMID:32522016)
• Long non-coding RNA SNHG7 promotes neuroblastoma progression through sponging miR-323a-5p and miR-342-5p. (PMID:32534305)
• ELK1/lncRNA-SNHG7/miR-2682-5p feedback loop enhances bladder cancer cell growth. (PMID:32898531)
• LncRNA-SNHG7 interferes with miR-34a to de-sensitize gastric cancer cells to cisplatin. (PMID:33074217)
• lncRNASNHG7003 inhibits the proliferation, migration and invasion of vascular smooth muscle cells by targeting the miR13065p/SIRT7 signaling pathway. (PMID:33416100)
• MSC-derived exosomal lncRNA SNHG7 suppresses endothelial-mesenchymal transition and tube formation in diabetic retinopathy via miR-34a-5p/XBP1 axis. (PMID:33600866)
• SNHG7 and FAIM2 are up-regulated and co-expressed in colorectal adenocarcinoma tissues.", trans “SNHG7 a FAIM2 jsou ve tkani kolorektalniho karcinomu up-regulovany a koexprimovany. (PMID:33685194)
• LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 Axis. (PMID:33738672)
• Clinicopathological and prognostic value of long noncoding RNA SNHG7 in cancer patients: a meta-analysis. (PMID:33877655)
• MicroRNA-21 inhibits ovarian granulosa cell proliferation by targeting SNHG7 in premature ovarian failure with polycystic ovary syndrome. (PMID:34020163)
• Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson’s disease model by targeting the miR-425-5p/TRAF5/NF-kappaB axis. (PMID:34369042)
• The Prognostic Value of Long Non-Coding RNA SNHG7 in Human Cancer: A Meta-Analysis. (PMID:34375186)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.